Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
The Lancet. Oncology
|
July 5, 2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Bertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Blood
|
February 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
Julio C Chavez, Michael Dickinson, Javier Munoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Haematologica
|
August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Eclinicalmedicine
|
January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Haematologica
|
July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Blood Advances
|
November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy, Sven de Vos, Morton Coleman, et al.
Blood Cancer Discovery
|
November 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Simone Filosto, Saran Vardhanabhuti, Miguel A Canales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
Anas Younes, Ajay K Gopal, Scott E Smith, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
The Lancet. Oncology
|
July 5, 2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Bertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Blood
|
February 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
Julio C Chavez, Michael Dickinson, Javier Munoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Haematologica
|
August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Eclinicalmedicine
|
January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Haematologica
|
July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Blood Advances
|
November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy, Sven de Vos, Morton Coleman, et al.
Blood Cancer Discovery
|
November 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Simone Filosto, Saran Vardhanabhuti, Miguel A Canales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
Anas Younes, Ajay K Gopal, Scott E Smith, et al.
Page
of 7